EXECUTIVE SUMMARY The House Ways and Means Committee’s Subcommittee on Health convened a hearing to discuss how current legislation, regulations and other agency actions are shaping pharmaceutical and medical device innovation, prices and patient access. Topics discussed include praise for lower out-of-pocket costs as a result of the Inflation Reduction Act (IRA) yet concerns about the unintended impact of IRA… (Joyce, May 15, 2023) #340B, #Affordable Care Act, #Biosimilars, #Costs, #COVID-19, #Demonstration Programs, #Disproportionate Share Hospitals (DSH), #Drug Pricing, #Food and Drug Administration, #Generic Drugs, #Insurance Coverage, #Medical Devices, #Pharmacy Benefit Managers, #Rural Health